Elimination of hepatitis C virus infection in patients with haemophilia in Belgium: A single‐centre experience

Fransen, Lennert; D'hondt, Pauline; Bielen, Rob; Ende, Natalie Van den; Robaeys, Geert; Peerlinck, Kathelijne; Nevens, Frederik

doi:10.1111/hae.13829

Cited by 8 publications

(7 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only three articles (9.4%) included in the review examined people with bleeding disorders and none examined transplant patients, despite them being identified as an important HCV microelimination group that should be easy to reach via the health system. Fransen et al 22 described eliminating HCV among patients with bleeding disorders in a single center in Belgium, with 86% of participants obtaining a cure. This study could be replicated in many other centers and countries around the world.…”

Section: Discussionmentioning

confidence: 99%

A Global Systematic Review of Hepatitis C Elimination Efforts through Micro-Elimination

et al. 2022

View full text Add to dashboard Cite

Micro-elimination targets specific sub-populations and/or geographic settings for hepatitis C virus (HCV) elimination. This review reports on global HCV micro-elimination literature published from 2013-2020. Data were extracted from publications to report a score based on the four key components defining micro-elimination. Sustained virologic response (SVR) and treatment initiation proportions were calculated for each manuscript and grouped means of these estimates were compared depending on micro-elimination score and care setting. 83% of the studies were from high-income settings and mainly included people who use drugs or those incarcerated. Among manuscripts, 18 had ‘low’ micro-elimination scores, 11 had ‘high’ scores and the differences in mean proportion who initiated treatment and achieved SVR between low and high score groups were statistically significant. Micro-elimination can be a useful complementary strategy for driving engagement in HCV treatment and cure. Our analysis suggests that adhering to more of the core micro-elimination components can improve outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

A Global Systematic Review of Hepatitis C Elimination Efforts through Micro-Elimination

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Nine studies from Belgium, the USA, Japan, South Korea, New Zealand, Italy, China, and Portugal thus far measured SVR rate in patients with HBD and CHC; except two studies from the United States and Italy, as well as the present study, their sample sizes were less than 100 [3,7,17,[29][30][31][32][33][34]. The information of these studies is summarized in Table 4.…”

Section: Discussionmentioning

confidence: 87%

“…Fransen et al [29] performed a study in Belgium on 85 patients with HBD and CHC treated with DAAs. Of these 85 patients, the SVR rate was measured in 84, and 77 (91.6%) achieved SVR.…”

Section: Discussionmentioning

confidence: 99%

Treatment of hepatitis C virus infection with direct-acting antiviral agent-based regimens in Iranian patients with hereditary bleeding disorders

Sharafi

Behnava

Azizi-Saraji

et al. 2021

Virol J

View full text Add to dashboard Cite

Background Chronic hepatitis C (CHC) is one of the most important comorbidities in patients with hereditary bleeding disorders (HBD). The present study aimed at evaluating the effectiveness of direct-acting antiviral agent (DAA)-based interferon-free HCV antiviral regimens in patients with HBD. Patients and methods The present study was performed on the patients with HBD and CHC between 2015 and 2019. Sofosbuvir-based interferon-free regimens with or without ribavirin were prescribed to treat HCV infection. The main endpoint of the study was to determine the sustained virologic response (SVR), assessed 12 weeks after the completion of treatment. Results A total of 147 patients with a mean age of 41.1 years were enrolled in the study; 4.1% of them were co-infected with HIV, 25.2% had cirrhosis, and 76.9% of them were diagnosed with hemophilia A. HCV genotype-1 includes the largest number (68.1%) of patients. 46.3% of patients were treatment-naïve and others had a treatment history with interferon-based regimens. Out of 147 patients, 15 patients were lost to follow-up during treatment or for SVR evaluation or discontinued treatment. 132 subjects completed treatment and were evaluated for SVR, 12 weeks after the completion of treatment. All of the patients achieved SVR 12 (SVR rate: 100%, 95% CI 97.2–100%). Conclusion Hepatitis C DAA-based regimens are the effective treatments for CHC in patients with HBD, regardless of the treatment modifiers such as previous treatment experience, cirrhosis, HIV co-infection, and HCV genotype.

show abstract

“…The SVR rate, measured in 84 among them, was 91.6%. 69 A Portuguese retrospective analysis of a singlecenter cohort of HCV-infected haemophilia patients included 73 patients followed for 22 years. Among them, two treatment-naïve and 14 treatment-experienced patients were treated with DAAs, with an overall SVR-12 rate of 100%.…”

Section: Dovepressmentioning

confidence: 99%

Hepatitis C Virus Infections in Patients with Hemophilia: Links, Risks and Management

Spanoudaki¹,

Papadopoulos²,

Trifylli³

et al. 2022

JMDH

View full text Add to dashboard Cite

Haemophilia is a rare, hereditary bleeding disorder. Clotting factor concentrates were a revolutionary treatment which changed the life of people with haemophilia. However, early generation of clotting factor concentrates, without viral inactivation procedures in the manufacturing process, led to an increased risk of transmission of blood-borne viral infections, mainly due to hepatitis C virus and human immunodeficiency virus. As only 20% of HCV-infected patients clear the infection naturally, chronic HCV infection constitutes a serious health problem and a major cause of chronic liver disease in this group of patients. Fortunately, the use of viral inactivation procedures in the plasma-derived factor concentrates manufacturing process and the availability of alternative treatment options, led to a significant reduction of transfusion-associated viral infections. The advent of multiple, orally administrated, highly effective direct-acting antivirals (DAAs) is changing the natural history of HCV infection in patients with haemophilia as these drugs have an excellent safety profile and achieve very high sustained virological response rates, similar to the general population. Eradication of HCV-infection in patients with haemophilia is feasible via micro-elimination projects.

show abstract

Elimination of hepatitis C virus infection in patients with haemophilia in Belgium: A single‐centre experience

Cited by 8 publications

References 24 publications

A Global Systematic Review of Hepatitis C Elimination Efforts through Micro-Elimination

A Global Systematic Review of Hepatitis C Elimination Efforts through Micro-Elimination

Treatment of hepatitis C virus infection with direct-acting antiviral agent-based regimens in Iranian patients with hereditary bleeding disorders

Hepatitis C Virus Infections in Patients with Hemophilia: Links, Risks and Management

Contact Info

Product

Resources

About